Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma

Next Previous
X
Search
Trial Profile

A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selumetinib (Primary) ; Temozolomide
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 19 Mar 2013 Planned end date changed from 1 Apr 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to an AstraZeneca media release.
    • 02 Nov 2011 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top